Abstract Background Glucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells
Protective Cardiovascular Effects of GLP-1 There are also GLP-1 receptors in the brain which help activate nitric oxide synthase, causing vasodilatation to control blood pressure 4

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)

In Lillys TRIUMPH-1 study, adults with obesity or overweight and at least one weight-related condition received retatrutide or placebo
These risks include, but may not be limited to: Due to state licensure requirements of healthcare providers, you have to physically be in the state that your Medical Group Healthcare Provider is licensed in during your telehealth visit
[] Read More What Is a Medical Narrative Report, and Why Does It Matter in an Injury Case